asc40
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Apr 4, 2021 (NCT04843449)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06248008 | Phase 3 | Apr 18, 2024 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT06192264 | Phase 3 | Jan 23, 2024 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT05104125 | Phase 2 | Dec 20, 2021 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT05118776 | Phase 3 | Nov 18, 2021 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT04843449 | Phase 1 | Apr 4, 2021 | Ascletis Pharmaceuticals Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ascletis Pharmaceuticals Co., Ltd. | For profit | 5 | 5 | 3 | 2021 |
1 organizations
Page 1 / 1